Vertex Pharmaceuticals Incorporated (VRTX) compared with its closest peers (LLY, JNJ, ABBV, MRK, ABT): P/E 31.1 vs industry 17.2. Peer set by Business model: Big Pharma / Branded Drugs; 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Eli Lilly and Company (LLY) | $1.17T | 46.5 |
| Johnson & Johnson (JNJ) | $646.07B | 30.7 |
| AbbVie Inc. (ABBV) | $462.72B | 73.3 |
| Merck & Co., Inc. (MRK) | $367.12B | 115.7 |
| Abbott Laboratories (ABT) | $198.97B | 31.7 |
| Gilead Sciences, Inc. (GILD) | $178.07B | 19.3 |
| Pfizer Inc. (PFE) | $158.34B | 36.5 |
| Bristol-Myers Squibb Company (BMY) | $133.80B | 14.4 |
| Regeneron Pharmaceuticals, Inc. (REGN) | $87.65B | 20.8 |
| Zoetis Inc. (ZTS) | $31.47B | 11.9 |
| Stock P/E | 31.1 |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| vs Sector | 44.1% |
| vs Industry | 81.2% |
VRTX overview · VRTX earnings · VRTX financials · VRTX KPIs · VRTX investor relations · VRTX ownership · VRTX filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.